-
NHSA Revises 2024 NRDL Drug Information Based on Public Feedback
•
China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs on the 2024 National Reimbursement Drug List (NRDL) following public feedback. These changes reflect the NHSA’s commitment to transparency and responsiveness in managing the country’s drug reimbursement policies. Specific Drug UpdatesThe NHSA has confirmed that…
-
NHSA to Announce NRDL Adjustment Results at November 28th Press Conference
•
The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price bidding for the National Reimbursement Drug List (NRDL) adjustment at a press conference scheduled for 10:00 am on November 28th. This event marks a significant moment in the healthcare sector as it will disclose the…
-
National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate
•
The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than 50% of the total 162 participating generic name drugs passing the expert review. This approval rate is a decrease compared to 74.2% in 2022 and 63.8% in 2023. The successful drugs included 117 varieties from…
-
Jiangxi Province to Implement Direct Medical Insurance Fund Payments for NRDL Drugs from December 2024
•
The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly issued a notification to initiate direct payment settlement between the medical insurance fund and pharmaceutical suppliers for National Reimbursement Drug List (NRDL) negotiation drugs starting December 1, 2024. This move signifies a shift towards streamlining…
-
China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding
•
The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding for the adjustment of the National Reimbursement Drug List (NRDL) will be conducted from October 27 to 30 in Beijing, with results anticipated to be released next month. The updated version of the NRDL is…
-
NHSA Preliminary Review Identifies Potential NRDL Additions, Including Novel Therapies and ADCs
•
The National Healthcare Security Administration (NHSA) has released a preliminary list of drugs that have passed the initial formal review stage for potential inclusion in the National Reimbursement Drug List (NRDL) for this year, with a public feedback period open until August 18, 2024. The NHSA received a total of…
-
NHSA Seeks Public Input on National Reimbursement Drug List Adjustments
•
The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement Drug List (NRDL) for the current year and is soliciting public feedback until June 19, 2024. The NHSA has outlined the criteria for drug inclusion, which aligns with previous years’ requirements. Eligibility for inclusion on…
-
Jiangsu Province Announces Dual Channel Management and Separate Payment Drug List
•
Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel management and separate payment, focusing on those added to the National Reimbursement Drug List (NRDL) through negotiations this year. A total of 74 drugs fall under “dual channel” management, with 36 designated for separate payment.…
-
Hunan Province Releases “Dual Channel” Drug Payment List with 226 Products
•
The Hunan Healthcare Security Administration has published a list of 226 drugs to be included under the “dual channel” single-line payment management system, which includes 43 newly added products from the 2023 National Reimbursement Drug List (NRDL) negotiations. The targeted drugs are characterized by high clinical value, urgent need, and…
-
China’s 2023 NRDL Expands Coverage with 126 New Drugs, Aims for Savings and Accessibility
•
The National Healthcare Security Administration (NHSA) has released the finalized National Reimbursement Drug List (NRDL) for 2023, adding 126 new drugs to the list. The new additions include 21 oncology drugs, 17 COVID-19 treatments, 15 drugs for diabetes, mental illness, and rheumatoid/immune diseases, and 15 rare disease drugs. The NRDL…
-
National Reimbursement Drug List Negotiations and Bidding Process Conclude
•
The on-site negotiation and bidding processes for the 2023 update to China’s National Reimbursement Drug List (NRDL) commenced on November 17, 2023, and concluded on November 20, lasting a total of four days. The National Healthcare and Security Administration (NHSA) selected 25 experts to carry out the negotiations, which were…
-
NHSA Completes Expert Review for National Reimbursement Drug List Updates
•
The National Healthcare Security Administration (NHSA) has announced the completion of the expert review stage for drugs under consideration for inclusion in the upcoming update to the National Reimbursement Drug List (NRDL). This marks a significant step forward in the annual process, which determines which medications will be covered by…
-
Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs
•
The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at enhancing access to drugs from the National Reimbursement Drug List (NRDL). This program involves 23 designated medical institutions within the city, chosen for their high outpatient volumes and low procurement of national negotiation drugs, which…
-
NHSA Clears Retagliptin and Ambroxol for National Reimbursement Drug List Inclusion
•
The National Healthcare Security Administration (NHSA) has completed a review of the National Reimbursement Drug List (NRDL) adjustment formality review results for retagliptin and ambroxol. Both drugs, first approved for marketing in China in June 2023 and July 2019 respectively, have been deemed eligible for the filing requirement stipulating “new…
-
NHSA Releases Preliminary Review Results for National Reimbursement Drug List Adjustments
•
The National Healthcare Security Administration (NHSA) has released a notification disclosing the drugs that have passed the preliminary formal review stage for potential inclusion in this year’s adjustment to the National Reimbursement Drug List (NRDL). The public feedback window is open from August 18 to 24, 2023, allowing stakeholders to…
-
NHSA Unveils Updated National Reimbursement Drug List Rules for 2023
•
The National Healthcare Security Administration (NHSA) has released the updated rules that will govern this year’s National Reimbursement Drug List (NRDL) update. The revisions focus on “Negotiation Drug Renewals” and “Non-exclusive Drug Bidding,” with significant changes to the negotiation drug renewals process, indicating reduced pressure on innovative drugs undergoing renewals.…
-
NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties
•
The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement Drug List (NRDL) update. The finalized NRDL now includes a total of 2,967 drug varieties, comprising 1,586 western medicines, 1,381 Chinese patent drugs, and 892 traditional Chinese medicines in ready-to-use forms. Among western drugs, there…
-
NHSA Completes 2022 NRDL Update with 111 New Listings, Focus on COVID-19 Treatments
•
The National Healthcare Security Administration (NHSA) held a press conference to mark the completion of the delayed 2022 National Reimbursement Drug List (NRDL) update. A total of 111 new drug listings were added, while three drugs were removed from the list. This year’s adjustment is expected to save RMB 90…
-
Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute
•
The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) notably absent despite widespread anticipation. The National Healthcare Security Administration (NHSA) cited a failure to agree on a price point as the reason for Paxlovid’s exclusion. Industry observers speculated that the NHSA…
-
NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions
•
The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the National Reimbursement Drug List (NRDL) on-site negotiations process for this year, citing COVID-19 disruptions and ongoing workload related to preparing for the negotiations. When a new time slot is decided, the negotiating groups will be…
